JBCPL announces the change of its identity to JB, retaining its core value – ‘GOOD PEOPLE for GOOD HEALTH’

 While JB’s look has changed, the values remain!

Mumbai – 30th May 2022: JB Chemicals & Pharmaceuticals Limited, the fastest growing pharmaceuticals company in India, has emerged in a new avatar as JB, retaining its core value of being ‘Good people for good health’. The company announced its new identity in a media conference organised on May 27, 2022, at The Four Seasons, Worli, Mumbai. 

In sync with the evolving healthcare industry, and the changing need of customers, JB has re-visioned the cause of spreading good health in India. JB aims to support healthcare providers and enrich patients’ lives in innovative new ways while remaining committed to its core values of integrity, trust and reliability built over 45 years.

Announcing the change of identity to JB – Good People for Good Health, Mr Nikhil Chopra, CEO & Whole-time Director, JB, said, “In 45 years, we, at JB, have built a strong foundation of integrity, trust and reliability. Now we are taking the next leap forward towards becoming more agile, lean and simple. Our offerings and capabilities are becoming more diverse to cater to the evolving needs of our customers, our manufacturing processes are becoming more robust, and lean, our vision of looking at healthcare industry is becoming more progressive, globally. We are adapting ourselves to become more responsive to the needs of the healthcare world.”

Adding further, Mr Chopra said, “While we are changing in many ways, we are not changing the solid foundation of JB. Our new identity has a simple, solid look that reflects the way we think and conduct ourselves. It is a symbol of our belief in being ‘Good People for Good Health’.”

Catering to the evolving needs of customers (patients), JB has been adapting to the emerging new technologies and acquiring the leading pharma brands. The recent acquisition of Sanzyme has helped JB gain ranks and figures in the top-25 brands of the Indian Pharmaceutical Market. Likewise, by the acquisition of Azmarda in April 2022, JB is likely to surge more ranks in the Indian Pharmaceutical Market. 

JB has emerged as the fastest growing Indian Pharmaceutical company. It has figured among the top 25 pharma companies with a remarkable growth rate of 29% in the Financial Year 2021-22. The five household brands of JB have featured in the top 300 of the Indian Pharmaceutical Market (IPM) with 4 brands (including Azmarda) in the top 100 in the cardiac therapy segment. JB currently ranks at 12 in the gastro-intestinal segment in IPM. It has over 350 brands with 20 key therapeutic categories. Its brands are available across 600,000 pharmacies in India, literally, in almost every PIN code. 

The 5 household brands of JB featured in the top 300 of the Indian Pharmaceutical Market (IPM) are – Rantac (anti-ulcerate) with IPM rank at 45 and gastro-intestinal segment rank at 6; Cilacar (anti-hypertensive) with rank at 52 and cardiac segment rank at 4; Cilacar-T (anti-hypertensive) with rank at 203 and cardiac segment rank at 22; Metrogyl (amoebicide) with IPM rank at 194; Nicardia (anti-hypertensive) with rank at 240 and cardiac segment rank at 30. 

Its seven manufacturing facilities in India comply to the world’s highest standards meeting the rigorous international regulatory requirements around the world. It is one of the few Indian pharma companies employing the OROS (Osmotic-controlled release oral delivery system) technology. JB has set an unmatched technological lead in lozenges as a drug delivery format and is today one of the world’s top 5 manufacturers of medicated and herbal lozenges.

It has over 40 highest global accreditations for the manufacturing process including certification from the US, UK, EU, Australia, South Africa, Russia/CIS and Australia. JB exports a wide range of formulations to over 40+ regulated and semi-regulated markets. JB is among the top 15 companies in the South Africa regulated market with a strong public and private presence. In Russia, JB has over 30 years of brand equity and a direct presence with field force in the high growth OTC segment. It is a leading partner for global pharma innovators and Global MNC majors.